Literature DB >> 3187199

Chronic primidone treatment in the rat: an animal model of primidone therapy.

G F Carl1, M L Smith.   

Abstract

A continuously protective, nontoxic, oral model of chronic treatment with primidone was developed in the rat. Rats were treated with primidone (100 mg/kg) by gastric gavage twice daily for up to 8 weeks. This treatment was continuously protective as measured by seizures induced by hexafluorodiethyl ether and minimally toxic as measured by weight gain. Plasma primidone concentration reached a peak (13 micrograms/ml) 2 hours after gavage and was almost undetectable by 12 hours. Plasma phenobarbital concentration peaked (52 micrograms/ml) at 6 hours postgavage after reaching a minimum (19 micrograms/ml) at one hour postgavage. Phenobarbital concentrations measured in plasma, brain and liver after 8 weeks of chronic treatment correlated significantly between each tissue and plasma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3187199

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  2 in total

1.  Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat.

Authors:  S Nagaki; N Ratnaraj; P N Patsalos
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jul-Sep       Impact factor: 2.569

Review 2.  Cognitive impairment in childhood onset epilepsy: up-to-date information about its causes.

Authors:  Eun-Hee Kim; Tae-Sung Ko
Journal:  Korean J Pediatr       Date:  2016-04-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.